Crosspoint Capital Strategies’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Crosspoint Capital Strategies’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-205,152	Closed	-$7.13M	–	933
2015 Q2	$7.13M	Buy	+205,152	New	+$6.26M	2.02%	7
2014 Q2	–	Sell	-981	Closed	-$15K	–	668
2014 Q1	$15K	Hold	981	–	–	0.01%	411
2013 Q4	$13K	Buy	+981	New	+$5.29K	﹤0.01%	399

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Crosspoint Capital Strategies's HZNP Position: Q3 2015 in Review

Crosspoint Capital Strategies sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2015, closing a stake of 205,152 shares — an estimated $7.13M sold.

Crosspoint Capital Strategies first reported a position in HZNP in Q4 2013 and held it in 3 quarters. The position peaked at $7.13M in Q2 2015. 223 funds tracked by Wall St. Rank hold HZNP as of Q3 2015.

Crosspoint Capital Strategies reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2015 after selling out during the quarter.
Crosspoint Capital Strategies sold 205,152 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2015, an estimated $7.13M.
Crosspoint Capital Strategies first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2013 and held it in 3 quarters.
Crosspoint Capital Strategies's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $7.13M in Q2 2015.
223 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q3 2015, filed 25 Nov 2015.